Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
about
Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cellsQuinomycin A targets Notch signaling pathway in pancreatic cancer stem cellsProton NMR study of the [d(ACGTATACGT)]2-2echinomycin complex: conformational changes between echinomycin binding sites.
P2860
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@ast
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@en
type
label
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@ast
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@en
prefLabel
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@ast
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@en
P2093
P1476
Phase I trial of echinomycin ( ...... y 24-hour continuous infusion.
@en
P2093
Coltman CA
Von Hoff DD
P304
P356
10.1016/0277-5379(89)90123-5
P577
1989-05-01T00:00:00Z